BIOMAT Database Logo BIOMAT Database Logo

In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone. 2010

Brian J Morrow, and Wenping He, and Karen M Amsler, and Barbara D Foleno, and Mark J Macielag, and A Simon Lynch, and Karen Bush
Johnson & Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ 08869, USA.

JNJ-Q2, a novel fluorinated 4-quinolone, was evaluated for its antibacterial potency by broth and agar microdilution MIC methods in studies focused on skin and respiratory tract pathogens, including strains exhibiting contemporary fluoroquinolone resistance phenotypes. Against a set of 118 recent clinical isolates of Streptococcus pneumoniae, including fluoroquinolone-resistant variants bearing multiple DNA topoisomerase target mutations, an MIC(90) value for JNJ-Q2 of 0.12 microg/ml was determined, indicating that it was 32-fold more potent than moxifloxacin. Against a collection of 345 recently collected methicillin-resistant Staphylococcus aureus (MRSA) isolates, including 256 ciprofloxacin-resistant strains, the JNJ-Q2 MIC(90) value was 0.25 microg/ml, similarly indicating that it was 32-fold more potent than moxifloxacin. The activities of JNJ-Q2 against Gram-negative pathogens were generally comparable to those of moxifloxacin. In further studies, JNJ-Q2 exhibited bactericidal activities at 2x and 4x MIC levels against clinical isolates of S. pneumoniae and MRSA with various fluoroquinolone susceptibilities, and its activities were enhanced over those of moxifloxacin. In these studies, the activity exhibited against strains bearing gyrA, parC, or gyrA plus parC mutations was indicative of the relatively balanced (equipotent) activity of JNJ-Q2 against the DNA topoisomerase target enzymes. Finally, determination of the relative rates or frequencies of the spontaneous development of resistance to JNJ-Q2 at 2x and 4x MICs in S. pneumoniae, MRSA, and Escherichia coli were indicative of a lower potential for resistance development than that for current fluoroquinolones. In conclusion, JNJ-Q2 exhibits a range of antibacterial activities in vitro that is supportive of its further evaluation as a potential new agent for the treatment of skin and respiratory tract infections.

UI MeSH Term Description Entries
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013296 Streptococcus pneumoniae A gram-positive organism found in the upper respiratory tract, inflammatory exudates, and various body fluids of normal and/or diseased humans and, rarely, domestic animals. Diplococcus pneumoniae,Pneumococcus
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D055624 Methicillin-Resistant Staphylococcus aureus A strain of Staphylococcus aureus that is non-susceptible to the action of METHICILLIN. The mechanism of resistance usually involves modification of normal or the presence of acquired PENICILLIN BINDING PROTEINS. MRSA,Methicillin Resistant Staphylococcus aureus
D024841 Fluoroquinolones A group of QUINOLONES with at least one fluorine atom and a piperazinyl group. Fluoroquinolone
D024881 Drug Resistance, Bacterial The ability of bacteria to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance, Bacterial,Antibacterial Drug Resistance

Related Publications

Brian J Morrow, and Wenping He, and Karen M Amsler, and Barbara D Foleno, and Mark J Macielag, and A Simon Lynch, and Karen Bush
Summary of Pharmacokinetics and Tissue Distribution of a Broad-Spectrum Fluoroquinolone, JNJ-Q2.
October 2012, Clinical pharmacology in drug development,
Brian J Morrow, and Wenping He, and Karen M Amsler, and Barbara D Foleno, and Mark J Macielag, and A Simon Lynch, and Karen Bush
In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.
April 2000, The Journal of antimicrobial chemotherapy,
Brian J Morrow, and Wenping He, and Karen M Amsler, and Barbara D Foleno, and Mark J Macielag, and A Simon Lynch, and Karen Bush
In vitro and in vivo antibacterial activities of CFC-222, a novel broad spectrum fluoroquinolone.
January 1995, Drugs,
Brian J Morrow, and Wenping He, and Karen M Amsler, and Barbara D Foleno, and Mark J Macielag, and A Simon Lynch, and Karen Bush
JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains.
July 2011, Antimicrobial agents and chemotherapy,
Brian J Morrow, and Wenping He, and Karen M Amsler, and Barbara D Foleno, and Mark J Macielag, and A Simon Lynch, and Karen Bush
In vitro and in vivo antibacterial activities of GV129606, a new broad-spectrum trinem.
December 1997, Antimicrobial agents and chemotherapy,
Brian J Morrow, and Wenping He, and Karen M Amsler, and Barbara D Foleno, and Mark J Macielag, and A Simon Lynch, and Karen Bush
In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone.
February 1990, Antimicrobial agents and chemotherapy,
Brian J Morrow, and Wenping He, and Karen M Amsler, and Barbara D Foleno, and Mark J Macielag, and A Simon Lynch, and Karen Bush
SCE-963, a new broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities.
October 1978, Antimicrobial agents and chemotherapy,
Brian J Morrow, and Wenping He, and Karen M Amsler, and Barbara D Foleno, and Mark J Macielag, and A Simon Lynch, and Karen Bush
In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
August 1989, Antimicrobial agents and chemotherapy,
Brian J Morrow, and Wenping He, and Karen M Amsler, and Barbara D Foleno, and Mark J Macielag, and A Simon Lynch, and Karen Bush
In vitro studies on the antibacterial activities of YM-13115, a new broad-spectrum cephalosporin.
April 1985, Antimicrobial agents and chemotherapy,
Brian J Morrow, and Wenping He, and Karen M Amsler, and Barbara D Foleno, and Mark J Macielag, and A Simon Lynch, and Karen Bush
In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
January 1992, Chemotherapy,
Copied contents to your clipboard!